Vandana G. Abramson, M.D.
- Donna S. Hall Chair in Breast Cancer
- Professor of Medicine (Hematology/Oncology)
Phone
Division of Hematology/Oncology
2220 Pierce Avenue, 777 PRB
Nashville, TN 37232-6307
Vandana G. Abramson, M.D.
- Donna S. Hall Chair in Breast Cancer
- Professor of Medicine (Hematology/Oncology)
(615) 936-3831
vandana.abramson@vumc.org
Division of Hematology/Oncology
2220 Pierce Avenue, 777 PRB
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Abramson is Professor of Medicine in the Division of Hematology/Oncology. After receiving her B.A. in English and Molecular & Cell Biology at the University of California, Berkeley, she went to medical school at the University of Chicago. Dr. Abramson completed her Internal Medicine Residency at Brigham and Women's Hospital in Boston, MA and Hematology/Oncology training at the University of Pennsylvania in Philadelphia, PA.
Dr. Abramson serves as the Principal Investigator on several breast cancer clinical trials at Vanderbilt. She is an active member in the American Society of Clinical Oncology.
Education
- M.D.: University of Chicago School of Medicine
- Residency: Brigham and Women's Hospital, Boston
- Fellowship: Hospital of the University of Pennsylvania
Research Emphasis
Publications
Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL. Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clin. Cancer Res [print-electronic]. 2017 Jul 7/15/2017; 23(14): 3520-8. PMID: 28031425, PII: 1078-0432.CCR-16-1764, DOI: 10.1158/1078-0432.CCR-16-1764, ISSN: 1078-0432.
Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin. Cancer Res [print-electronic]. 2017 Mar 3/7/2017; PMID: 28270498, PII: 1078-0432.CCR-16-3055, DOI: 10.1158/1078-0432.CCR-16-3055, ISSN: 1078-0432.
Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL. A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin. Cancer Res [print-electronic]. 2017 Jan 1/1/2017; 23(1): 26-34. PMID: 27126994, PMCID: PMC5085926, PII: 1078-0432.CCR-16-0134, DOI: 10.1158/1078-0432.CCR-16-0134, ISSN: 1078-0432.
Williams JM, Arlinghaus LR, Rani SD, Shone MD, Abramson VG, Pendyala P, Chakravarthy AB, Gorge WJ, Knowland JG, Lattanze RK, Perrin SR, Scarantino CW, Townsend DW, Abramson RG, Yankeelov TE. Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging. Eur. J. Nucl. Med. Mol. Imaging [print-electronic]. 2016 Dec; 43(13): 2374-80. PMID: 27557845, PMCID: PMC5096989, PII: 10.1007/s00259-016-3477-3, DOI: 10.1007/s00259-016-3477-3, ISSN: 1619-7089.
Henry NL, Somerfield MR, Abramson VG, Allison KH, Anders CK, Chingos DT, Hurria A, Openshaw TH, Krop IE. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. J. Clin. Oncol [print-electronic]. 2016 Jul 7/1/2016; 34(19): 2303-11. PMID: 27001586, PII: JCO.2015.65.8609, DOI: 10.1200/JCO.2015.65.8609, ISSN: 1527-7755.
Colonna SV, Higgins AK, Alvarez J, Saville BR, Lawrence J, Abramson VG. Analysis of Risk of Recurrence by Subtype in = 1-cm Breast Tumors. Clin. Breast Cancer [print-electronic]. 2016 Jun; 16(3): 223-31. PMID: 26683741, PII: S1526-8209(15)00239-6, DOI: 10.1016/j.clbc.2015.10.001, ISSN: 1938-0666.
Abramson RG, Lambert KF, Jones-Jackson LB, Arlinghaus LR, Williams J, Abramson VG, Chakravarthy AB, Yankeelov TE. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer. Acad Radiol [print-electronic]. 2015 Jul; 22(7): 853-9. PMID: 25865435, PMCID: PMC4464958, PII: S1076-6332(15)00109-9, DOI: 10.1016/j.acra.2015.02.012, ISSN: 1878-4046.
Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF, . Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin. Cancer Res [print-electronic]. 2015 Jun 6/15/2015; 21(12): 2771-9. PMID: 25779948, PMCID: PMC5521206, PII: 1078-0432.CCR-14-2781, DOI: 10.1158/1078-0432.CCR-14-2781, ISSN: 1078-0432.
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, . TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin. Cancer Res [print-electronic]. 2015 Jun 6/15/2015; 21(12): 2722-9. PMID: 25779953, PII: 1078-0432.CCR-14-2780, DOI: 10.1158/1078-0432.CCR-14-2780, ISSN: 1078-0432.
Ballinger TJ, Sanders ME, Abramson VG. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy. Clin. Breast Cancer [print-electronic]. 2015 Jun; 15(3): 171-80. PMID: 25516402, PII: S1526-8209(14)00267-5, DOI: 10.1016/j.clbc.2014.11.009, ISSN: 1938-0666.
